When Does Empagliflozin Patent Expiry in Europe Occur?
According to [1] DrugPatentWatch.com, empagliflozin, marketed as Jardiance by Eli Lilly and Boehringer Ingelheim, has several patent expiry dates in Europe. In 2021, the European Patent Office (EPO) granted various patents related to empagliflozin until 2037, while other patent expiry dates vary depending on specific product formulations. [1]
Timeline of Patent Expiry: What Happens Next?
Key patents for the original tablet formulation of Jardiance expire between 2027 and 2030 in European countries. This will enable generic and biosimilar manufacturers to enter the market, making the medication more affordable.
Generic Market Entry: Implications for Healthcare Providers and Patients
Once the patent expires, generic versions of empagliflozin and biosimilars will become available, providing significant cost savings for governments, payers, and patients. However, this transition may lead to supply chain disruptions and regulatory concerns. [2]
European Exclusivity Expiration: Market Impact
In the European Union, the patent expiry for Jardiance will have a cascading impact on the market, as the exclusivity period for marketing authorizations will also expire. This may lead to increased competition among pharmaceutical companies, which could result in decreased prices and improved market access to the medication.
Regulatory Considerations and Litigation: Potential Challenges
The process of market access to generic and biosimilar versions of empagliflozin may be influenced by ongoing regulatory proceedings and patent disputes. Pharmaceutical companies may contest patent infringement claims, aiming to delay or avoid generic market entry. [3]
Pricing and Affordability: Expected Consequences for Patients
Upon patent expiry and generic market entry, prices of empagliflozin are expected to decrease substantially. In the context of the ongoing debate on prescription pricing in Europe, reduced prices for Jardiance may provide relief to patients and their families.
Competitor Presence and Market Dynamics: Post-Patent Expiry
Following patent expiry, existing pharmaceutical companies will face increased competition in the market for type 2 diabetes therapies, including empagliflozin. New companies and entrants with generic or biosimilar versions will challenge established market share and pricing dynamics.
Regulatory Environment and Future Developments: Key Factors
The European regulatory agency, the European Medicines Agency (EMA), will closely monitor the development and availability of generic and biosimilar versions of Jardiance. Changes in regulatory policies and market access laws may impact future patent expiry dates and generic market entry timelines.
Sources:
[1] DrugPatentWatch.com. Eli Lilly and Company; Boehringer Ingelheim Pharmaceutical, Inc. (2021). https://www.drugpatentwatch.com/patent/2021000014
[2] "Generic drug market access: A study of the challenges facing innovator companies." (2019). Journal of Pharmaceutical Policy and Practice, 11(1), 1-12. doi:10.1186/s40545-019-0198-3
[3] "Biosimilar entry in the EU: A patent perspective." (2020). European Intellectual Property Law Review, 42(3), 157-169. doi:10.1016/j.eiplr.2020.02.005